A Phase 1, Randomized, Open-Label, Crossover Study to Investigate the Relative Bioavailability of LY4065967 Formulations in Healthy Participants

Eli Lilly and Company

Summary

The main purpose of this study is to compare 3 different forms of LY4065967 - a tablet and 2 types of capsule - to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 7 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 3 nights.

Eligibility

Age range: 18–55 years
Sex: All
Healthy volunteers: Yes

Detailed criteria

Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests. * Have clinical laboratory test results within normal reference range for the population or investigative site. * Have an electrocardiogram (ECG) at screening considered to be within acceptable limits by the investigator. * Have a body mass index within the range 18.0 to 35.0 kilograms per square meter (kg/m²) (inclusive). * Individuals assigned male at birth (AMAB) or assigned female at birth (AFAB) may participate in this trial. * Have venous a…

Interventions

Drug
LY4065967 Tablet
Administered orally
Drug
LY4065967 Formulated Capsule
Administered orally
Drug
LY4065967 Capsule
Administered orally

Locations (2)

Fortrea Clinical Research Unit
Daytona Beach, Florida
386-366-6400
Fortrea Clinical Research Unit
Dallas, Texas

A Phase 1, Randomized, Open-Label, Crossover Study to Investigate the Relative Bioavailability of LY4065967 Formulations in Healthy Participants

Summary

Eligibility

Interventions

Locations (2)

Compensation

Run this study?

Details

Conditions